Who
James M. Frates
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Amylyx Pharmaceuticals; Director, Sage Therapeutics; SVP, Alks Inc; CFO ALKS, Alkermes; SVP, CFO & Treasurer, Alkermes.
In numbers
- Trades disclosed
- 811
- Buys
- 3
- Sells
- 110
- Bought
- $291K
- Sold
- $45.5M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 2 May 2006
- Last trade
- 10 Sep 2026
- Last filed
- 14 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $315K9,768 at $32.27 | filing |
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $35K1,042 at $33.23 | filing |
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $315K9,768 at $32.27 | filing |
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $35K1,042 at $33.23 | filing |
| 18 Aug 2026filed 20 Aug 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —22,807 at $0.00 | filing |
| 18 Aug 2026filed 20 Aug 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —22,807 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —95,990 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —143,985 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —143,985 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —95,990 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $115K7,909 at $14.52 | filing |
| 2 Mar 2026filed 4 Mar 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $115K7,909 at $14.52 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $52K3,557 at $14.65 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $52K3,557 at $14.65 | filing |
| 6 Jan 2026filed 8 Jan 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $37K3,326 at $11.11 | filing |
| 6 Jan 2026filed 8 Jan 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $37K3,326 at $11.11 | filing |
| 30 Sep 2025filed 2 Oct 2025 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $155K10,558 at $14.65 | filing |
| 31 Jul 2025filed 31 Jul 2025 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code D | —19,154 | filing |
| 31 Jul 2025filed 31 Jul 2025 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code D | —21,500 | filing |
| 31 Jul 2025filed 31 Jul 2025 | Sage Therapeutics | SEC FORM 4 Code U | —2,845 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $39.00AMLX · dailypolitical.com · 18 Oct 2026Insider Selling: Amylyx Pharmaceuticals (NASDAQ:AMLX) Director Sells 30,000 Shares of StockAMLX · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name James M. Frates; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.